Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

BridgeBio Pharma (BBIO), a mid-cap biotech company, has investors thrilled with its commercial engine scaling following the approval of Acoramidis (brand name Attruby), a therapy for a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Additionally, the company is getting ready to introduce potentially three new products in 2026, pending approval. While BBIO stock is up more than 150% year to date, outpacing the S&P 500 Index ($SPX) gain of 15%, Wall Street sees more upside and ...